Mobilization of gastric histamine during repeated administration of a proton potassium adenosine triphosphatase inhibitor in intact and antrectomized rats.
Intact and antrectomized female rats were treated with the potent proton pump inhibitor, E3810 (daily 40 mg/kg weight, s.c.) for 4 weeks. Plasma gastrin concentration and urinary excretion of N-terminal big gastrin increased until day 14 and persisted at a high level in intact rats treated with E3810, but did not increase in antrectomized rats. Urinary excretion of histamine increased progressively and reached 7 times the control value following 4 weeks of treatment with E3810 in intact rats, but not in antrectomized rats. At the termination of the treatment, the endocrine cell density in the oxyntic mucosa of intact rats had increased by 85% with increased histamine content and elevated histidine decarboxylase activity, while antrectomized rats showed a low histamine level and low histidine decarboxylase activity. Administration of gastrin-17 I (10 micrograms/kg weight, sc) itself caused a significant increase in urinary excretion of histamine, which was inhibited by the specific gastrin receptor antagonist, L-365,260. These results suggests that the massive urinary excretion of histamine caused by the treatment with E3810 reflects gastrin-induced mobilization of gastric histamine and that neither E3810 itself nor E3810-induced luminal pH elevation has direct effects on mobilization of oxyntic mucosal histamine.
Miyazaki
Y
Y
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Shinomura
Y
Y
Higashimoto
Y
Y
Imamura
I
I
Fukui
H
H
Aoki
T
T
Okuda
Y
Y
Narita
T
T
Miwa
K
K
Miyazaki
I
I
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D002452:Cell Count / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005755:Gastrins / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000652:urine; D006632:Histamine / Q000032:analysis / Q000652:urine; D006636:Histamine Release / Q000187:drug effects*; D006640:Histidine Decarboxylase / Q000378:metabolism; D006728:Hormones / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D009853:Omeprazole / Q000031:analogs & derivatives; D010295:Parietal Cells, Gastric / Q000166:cytology / Q000187:drug effects; D011498:Protein Precursors / Q000652:urine; D011706:Pyloric Antrum / Q000601:surgery; D064750:Rabeprazole; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D005755:Gastrins; D006728:Hormones; D011498:Protein Precursors; D064750:Rabeprazole; C013706:big gastrin; C013550:gastrin 17; D006632:Histamine; D000251:Adenosine Triphosphatases; D006640:Histidine Decarboxylase; D009853:Omeprazole